PROT# CFTY720D2306: A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 1.25mg FTY720 Administered Orally Once Daily Versus Placebo in Patients with Primary Progressive Multiple Sclerosis

Project: Research project

Project Details

StatusFinished
Effective start/end date3/3/10 → 12/31/15

Funding

  • Novartis Pharmaceuticals Corporation (CFTY720D2306)